Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313890535> ?p ?o ?g. }
- W4313890535 endingPage "416" @default.
- W4313890535 startingPage "416" @default.
- W4313890535 abstract "Pancreatic cancer (PC) is one of the most lethal tumors in Europe with an overall 5-year survival rate of 5%. Since 1992, gemcitabine (Gem) has been the treatment of choice for metastatic disease with significant improvement in median overall survival (OS) compared to fluorouracil. A good performance status (PS) at diagnosis appears to be a strong predictive factor for better survival. Overall, 50% of PC are metastatic or locally advanced at diagnosis, and more than 70% of the resected patients will experience a recurrence, with a median OS ranging from 4 to 10 months (mos). FOLFIRINOX (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin) and Nab-paclitaxel (Nab-p) plus Gem have recently increased survival of patients with metastatic PC, over Gem. Treatment with FOLFIRINOX is generally considered more effective with respect to the doublet, with toxicity concerns, FOLFIRINOX achieves an overall response rate (ORR) of 31.6%, while for Nab-p plus Gem ORR is 23%; however, FOLFIRINOX was associated with higher rates of grade 3 and higher adverse events. Although the international guidelines indicate that both regimens can be used as first-line therapy for patients with metastatic PC, FOLFIRINOX is the most widely used; Nab-p plus Gem is more frequently used in patients with lower PS. In this review, we critically analyze these two regimens to give a pragmatic guide to treatment options." @default.
- W4313890535 created "2023-01-10" @default.
- W4313890535 creator A5002745641 @default.
- W4313890535 creator A5017658694 @default.
- W4313890535 creator A5023215623 @default.
- W4313890535 creator A5056669813 @default.
- W4313890535 creator A5064858820 @default.
- W4313890535 date "2023-01-08" @default.
- W4313890535 modified "2023-10-18" @default.
- W4313890535 title "Optimizing First-Line Chemotherapy in Metastatic Pancreatic Cancer: Efficacy of FOLFIRINOX versus Nab-Paclitaxel Plus Gemcitabine" @default.
- W4313890535 cites W1563878414 @default.
- W4313890535 cites W1864471800 @default.
- W4313890535 cites W1906085213 @default.
- W4313890535 cites W1931508686 @default.
- W4313890535 cites W1967156508 @default.
- W4313890535 cites W1968323734 @default.
- W4313890535 cites W1987313243 @default.
- W4313890535 cites W1996472967 @default.
- W4313890535 cites W2010833449 @default.
- W4313890535 cites W2012846370 @default.
- W4313890535 cites W2015943054 @default.
- W4313890535 cites W2027389238 @default.
- W4313890535 cites W2035758159 @default.
- W4313890535 cites W2036064715 @default.
- W4313890535 cites W2045246542 @default.
- W4313890535 cites W2066969492 @default.
- W4313890535 cites W2067339200 @default.
- W4313890535 cites W2069733373 @default.
- W4313890535 cites W2072569230 @default.
- W4313890535 cites W2079418758 @default.
- W4313890535 cites W2081622541 @default.
- W4313890535 cites W2083452953 @default.
- W4313890535 cites W2097642908 @default.
- W4313890535 cites W2101465269 @default.
- W4313890535 cites W2109636091 @default.
- W4313890535 cites W2111970355 @default.
- W4313890535 cites W2115658806 @default.
- W4313890535 cites W2129791148 @default.
- W4313890535 cites W2137104454 @default.
- W4313890535 cites W2151253787 @default.
- W4313890535 cites W2151906733 @default.
- W4313890535 cites W2161479848 @default.
- W4313890535 cites W2161884651 @default.
- W4313890535 cites W2164286021 @default.
- W4313890535 cites W2165480504 @default.
- W4313890535 cites W2170202192 @default.
- W4313890535 cites W2171435320 @default.
- W4313890535 cites W2176387555 @default.
- W4313890535 cites W2336712664 @default.
- W4313890535 cites W2415398754 @default.
- W4313890535 cites W2480793872 @default.
- W4313890535 cites W2481516632 @default.
- W4313890535 cites W2531887049 @default.
- W4313890535 cites W2536154437 @default.
- W4313890535 cites W2585204552 @default.
- W4313890535 cites W2590683350 @default.
- W4313890535 cites W2595351273 @default.
- W4313890535 cites W2596106368 @default.
- W4313890535 cites W2599017064 @default.
- W4313890535 cites W2735949777 @default.
- W4313890535 cites W2775404374 @default.
- W4313890535 cites W2780727948 @default.
- W4313890535 cites W2885447570 @default.
- W4313890535 cites W2901746942 @default.
- W4313890535 cites W2920167237 @default.
- W4313890535 cites W2937970119 @default.
- W4313890535 cites W2945349403 @default.
- W4313890535 cites W2947826965 @default.
- W4313890535 cites W2994227810 @default.
- W4313890535 cites W3000234716 @default.
- W4313890535 cites W3038632602 @default.
- W4313890535 cites W3119005666 @default.
- W4313890535 cites W3158634056 @default.
- W4313890535 cites W3161080579 @default.
- W4313890535 cites W3162603367 @default.
- W4313890535 cites W3185666883 @default.
- W4313890535 cites W3191080172 @default.
- W4313890535 cites W3200667602 @default.
- W4313890535 cites W3216297924 @default.
- W4313890535 cites W4282919273 @default.
- W4313890535 doi "https://doi.org/10.3390/cancers15020416" @default.
- W4313890535 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36672366" @default.
- W4313890535 hasPublicationYear "2023" @default.
- W4313890535 type Work @default.
- W4313890535 citedByCount "2" @default.
- W4313890535 countsByYear W43138905352023 @default.
- W4313890535 crossrefType "journal-article" @default.
- W4313890535 hasAuthorship W4313890535A5002745641 @default.
- W4313890535 hasAuthorship W4313890535A5017658694 @default.
- W4313890535 hasAuthorship W4313890535A5023215623 @default.
- W4313890535 hasAuthorship W4313890535A5056669813 @default.
- W4313890535 hasAuthorship W4313890535A5064858820 @default.
- W4313890535 hasBestOaLocation W43138905351 @default.
- W4313890535 hasConcept C121608353 @default.
- W4313890535 hasConcept C126322002 @default.
- W4313890535 hasConcept C143998085 @default.
- W4313890535 hasConcept C2776694085 @default.
- W4313890535 hasConcept C2777148230 @default.